Targeted Therapies Licensing and Partnering Summit Asia

With fast, cost-effective clinical infrastructure, generous government incentives, and simplified regulatory pathways, Asia’s biotech ecosystem has emerged as a global launchpad for innovation. Western pharma and biotech companies are increasingly turning to de-risked assets from Asia to supercharge their clinical pipelines and gain a competitive edge.

Already running in the US, the Targeted Therapies Partnering and Licensing Summit Asia is built to gather a regional, critical mass of ADC, Bispecific Antibody, T-Cell Engager, Targeted Protein Degradation, and Radiopharmaceutical platforms and pipelines, so that global multi-national (MNC) pharma can connect with biotech business development and discuss new licensing and co-development opportunities.

For NewCo, private and public biotech or small pharma, this accessible forum offers:

High seniority and quality of attendees across pharma and other biotech
Targeted focus, purpose-built format, and One-on-One Partnering™ portal allowing you to make meaningful connections easier and more efficient
Informative presentations and discussions nuanced to considerations for deal-making across targeted therapies
Global exposure, local advantage. Pharma can assess related programs back-to-back and biotech can meet multiple, international big pharma.